Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899041 | 0.90 | CYP3A4 (0.52) | CYP3A4CYP2C19LMNAALDH1A1MAPT | |
| SCHEMBL6897464 | 0.90 | CYP3A4 (0.42) | CYP3A4CYP2C19LMNAALDH1A1MAPT | |
| SCHEMBL6674132 | 0.83 | CYP3A4 (0.47) | CYP3A4CYP2C19LMNAALDH1A1MAPT | |
| SCHEMBL6782760 | 0.82 | CYP3A4 (0.66) | CYP3A4CYP2C19LMNAALDH1A1MAPT | |
| SCHEMBL6897563 | 0.81 | KMT2A (0.52) | CYP3A4CYP2C19LMNAALDH1A1MAPT | |
| SCHEMBL6898814 | 0.79 | CYP3A4 (0.42) | CYP3A4CYP2C19LMNAALDH1A1MAPT | |
| SCHEMBL6898372 | 0.78 | CYP3A4 (0.47) | CYP3A4CYP2C19LMNAALDH1A1MAPT | |
| SCHEMBL6896916 | 0.75 | ALDH1A1 (0.40) | CYP3A4CYP2C19LMNAALDH1A1MAPT | |
| SCHEMBL6896729 | 0.74 | KMT2A (0.52) | LMNAALDH1A1MAPTNPSR1NPC1 | |
| SCHEMBL6897989 | 0.74 | KMT2A (0.41) | CYP3A4CYP2C19LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683184-B2 | ANTITUMOR AGENTS | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2004-01-27 | — | — | US | disclosed |
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092910-A1 | Piperazine derivatives and process for the preparation thereof | CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS | CYP3A4 339/4885CYP2C19 1186/4885LMNA 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.